Previous 10 | Next 10 |
Gainers: Finch Therapeutics (FNCH) +46%. Zymeworks (ZYME) +44%. Lantheus (LNTH) +13%. BeiGene (BGNE) +12%. Inari Medical (NARI) +11%. Losers: Accolade (ACCD) -55%. Aldeyra Therapeutics (ALDX) -15%. Venus Concept (VERO) -14%. Bio...
GTY Technology (GTYH) +119% as investment firm agrees to pay 123% premium in taking the company private. Finch Therapeutics (FNCH) +63% as FDA lifts clinical hold on antibacterial drug. Zymeworks (ZYME) +47% on $10.50/share takeover bid. Lantheus Holdings (LNTH)&...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s the beginning of the end as we break down all of the biggest pre-market stock movers for Friday! Source: Eric Urquhart/Shutterstock.com News out of China, earnings, FDA updates, and more have stocks on t...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today confirmed it has received an unsolicited, non-binding proposal from All Blue Falcons FZE (“ABF”) and its affiliates to purchase the Com...
Update 5:35pm: Updates to include All Blue confirming bid in a 13D filing. Zymeworks (NYSE:ZYME) soared 46% in after hours trading after All Blue Falcons made a $773 million offer for the developer of antibody therapies for cancer. All Blue, which has a 5.4% stake in Zymeworks, made...
Zymeworks (NYSE:ZYME) soared 46% in after hours trading on a report that All Blue Capital made a $773 million offer for the developer of antibody therapies for cancer. All Blue made a on-binding offer of $10.50/share in cash, according to a Reuters report. Developing story ......
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it has completed enrollment in its global HERIZON-BTC-01 pivotal clinical trial evaluating the antitumor activity of zanidatamab monot...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced, in conjunction with its Asia Pacific partner BeiGene, the acceptance of two abstracts for poster presentations at the upcoming 2022 ASCO Annual Meeting ta...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its first quarter 2022 financial results after market close on May 4 th , 2022. Following the announcement, management will...
Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate Virtual R&D Day scheduled for today at 4:15 p.m. EDT SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: B...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...